Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector10715510.17816/1028-9984-2021-26-2-57-64ReviewsНаучные обзорыReview ArticleThe evolution of modern notions about bladder cancerЭволюция современного представления о раке мочевого пузыряhttps://orcid.org/0000-0003-0979-6909YurchenkoArtem A.ЮрченкоАртем Анатольевич
Russian Federation
likebrando@yandex.ruhttps://orcid.org/0000-0002-0887-00816308-6260FirsovMikhail A.ФирсовМихаил Анатольевич
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

firsma@mail.ruhttps://orcid.org/0000-0002-7210-30203632-8415ZukovRuslan A.ЗуковРуслан Александрович
Russian Federation

Dr. Sci. (Med.), Professor

д.м.н., профессор

zukov_rus@mail.ruhttps://orcid.org/0000-0002-3787-31262097-0304SlepovEvgeny V.СлеповЕвгений Владимирович
Russian Federation

MD, Cand. Sci. (Biol.)

к.биол.н.

slepov99@mail.ruKrasnoyarsk Clinical Regional HospitalКГБУЗ «Красноярская краевая клиническая больница»Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical UniversityФГБОУ ВО «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого»Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I.Kryzhanovsky RSBHEКГБУЗ «Красноярский краевой клинический онкологический диспансер имени А.И. Крыжановского»1504202126257640605202223062022Copyright ©; 2021, Yurchenko A.A., Firsov M.A., Zukov R.A., Slepov E.V.Copyright ©; 2021, Юрченко А.А., Фирсов М.А., Зуков Р.А., Слепов Е.В.2021Yurchenko A.A., Firsov M.A., Zukov R.A., Slepov E.V.Юрченко А.А., Фирсов М.А., Зуков Р.А., Слепов Е.В.https://creativecommons.org/licenses/by-nc-nd/4.0/https://rjonco.com/1028-9984/article/view/107155

The review details the evolution in the researchers’ perspective of bladder cancer over the past five decades. The history of the study, pathogenesis, etiology, and the clinical significance of urinary bladder are briefly discussed. The review presents currently prominent theories regarding the pathogenesis of urinary bladder neoplasms and the foundational research in this field. The article briefly discusses the molecular changes the development of bladder cancer and studies of the urine microbiome during oncogenesis

В обзоре отражены изменения, произошедшие в представлении исследователей рака мочевого пузыря за последние 50 лет. Произведён краткий экскурс в историю исследования, патогенез, этиологию, клиническую значимость уротелиального рака. Рассмотрены главенствующие в данный момент теории патогенеза опухолей уротелия, работы и исследования, на которые они опираются. Затронуты вопросы молекулярного изменения при развитии рака мочевого пузыря, исследования микробиома мочи при онкогенезе.

bladder cancerurinary bladder neoplasmsetiology of urinary bladder neoplasmstheory of carcinogenesisepidemiology of bladder cancermolecular carcinogenesisurinary bladderрак мочевого пузыряопухоли мочевого пузыряэтиология опухолей мочевого пузырятеории канцерогенезаэпидемиология рака мочевого пузырямолекулярный канцерогенезуротелиальный ракAssotsiatsiya onkologov Rossii. Klinicheskie rekomendatsii. Rak mochevogo puzyrya. 2020. (In Russ).Ассоциация онкологов России. Клинические рекомендации. Рак мочевого пузыря. 2020.Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 // Eur J Cancer. 2013. Vol. 49, N 6. P. 1374–1403. doi: 10.1016/j.ejca.2012.12.027Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–3044. doi: 10.1002/ijc.21731Parkin D.M. The global health burden of infection-associated cancers in the year 2002 // Int J Cancer. 2006. Vol. 118, N 12. P. 3030–3044. doi: 10.1002/ijc.21731Shiff C, Veltri R, Naples J, et al. Ultrasound verification of bladder damage is associated with known biomarkers of bladder cancer in adults chronically infected with Schistosoma haematobium in Ghana. Trans R Soc Trop Med Hyg. 2006;100(9):847–854. doi: 10.1016/j.trstmh.2005.10.010Shiff C., Veltri R., Naples J., et al. Ultrasound verification of bladder damage is associated with known biomarkers of bladder cancer in adults chronically infected with Schistosoma haematobium in Ghana // Trans R Soc Trop Med Hyg. 2006. Vol. 100, N 9. P. 847–854. doi: 10.1016/j.trstmh.2005.10.010Leonov MG, Shelyakina TV, Tkhagapso AA. Otsenka faktorov riska vozniknoveniya raka mochevogo puzyrya. Glavnyi vrach Yuga Rossii. 2015;(2):34. (In Russ).Леонов М.Г., Шелякина Т.В., Тхагапсо А.А. Оценка факторов риска возникновения рака мочевого пузыря // Главный врач Юга России. 2015. № 2. С. 34.Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89(3):630–639. doi: 10.1002/1097-0142(20000801)89:3<630::aid-cncr19>3.3.co;2-hZeegers M.P., Tan F.E., Dorant E., van Den Brandt P.A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies // Cancer. 2000. Vol. 89, N 3. P. 630–639. doi: 10.1002/1097-0142(20000801)89:3<630::aid-cncr19>3.3.co;2-hWallace DM. Occupational urothelial cancer. Br J Urol. 1988;61(3):175–182. doi: 10.1111/j.1464-410x.1988.tb06374.xWallace D.M. Occupational urothelial cancer // Br J Urol. 1988. Vol. 61, N 3. P. 175–182. doi: 10.1111/j.1464-410x.1988.tb06374.xMoore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17(9):2876–2881. doi: 10.1200/JCO.1999.17.9.2876Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group // J Clin Oncol. 1999. Vol. 17, N 9. P. 2876–2881. doi: 10.1200/JCO.1999.17.9.2876Shinka T, Sawada Y, Morimoto S, et al. Clinical study on urothelial tumors of dye workers in Wakayama City. J Urol. 1991;146(6):1504–1507. doi: 10.1016/s0022-5347(17)38151-xShinka T., Sawada Y., Morimoto S., et al. Clinical study on urothelial tumors of dye workers in Wakayama City // J Urol. 1991. Vol. 146, N 6. P. 1504–1507. doi: 10.1016/s0022-5347(17)38151-xHarris AL, Neal DE. Bladder cancer – field versus clonal origin. N Engl J Med. 1992;326(11):759–761. doi: 10.1056/NEJM199203123261108Harris A.L., Neal D.E. Bladder cancer – field versus clonal origin // N Engl J Med. 1992. Vol. 326, N 11. P. 759–761. doi: 10.1056/NEJM199203123261108Davidson DD, Cheng L. “Field cancerization” in the urothelium of the bladder. Anal Quant Cytol Histol. 2006;28(6):337–338.Davidson D.D., Cheng L. “Field cancerization” in the urothelium of the bladder // Anal Quant Cytol Histol. 2006. Vol. 28, N 6. P. 337-338.Wolf H, Hojgaard K. Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences. Lancet. 1983;2(8342):134–136. doi: 10.1016/s0140-6736(83)90117-4Wolf H., Hojgaard K. Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences // Lancet. 1983. Vol. 2, N 8342. P. 134–136. doi: 10.1016/s0140-6736(83)90117-4Sidransky D, Frost P, Von Eschenbach A, et al. Clonal origin of bladder cancer. N Engl J Med. 1992;326(11):737–740. doi: 10.1056/NEJM199203123261104Sidransky D., Frost P., Von Eschenbach A., et al. Clonal origin of bladder cancer // N Engl J Med. 1992. Vol. 326, N 11. P. 737–740. doi: 10.1056/NEJM199203123261104Lunec J, Challen C, Wright C, et al. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet. 1992;339(8790):439–440. doi: 10.1016/0140-6736(92)90135-pLunec J., Challen C., Wright C., et al. c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder // Lancet. 1992. Vol. 339, N 8790. P. 439–440. doi: 10.1016/0140-6736(92)90135-pBabaian AIu, Andreeva YuYu, Zaletaev DV, Nemtsova MV. Clonal origin of multiple foci of urinary bladder cancer. Arkhiv Patologii. 2012;74(5):44–50. (In Russ).Бабаян А.Ю., Андреева Ю.Ю., Залетаев Д.В., Немцова М.В. Клональное происхождение множественных очагов рака мочевого пузыря // Архив патологии. 2012. Т. 74, № 5. С. 44–50.Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11(18):6512–6519. doi: 10.1158/1078-0432.CCR-05-0891Jones T.D., Wang M., Eble J.N., et al. Molecular evidence supporting field effect in urothelial carcinogenesis // Clin Cancer Res. 2005. Vol. 11, N 18. P. 6512–6519. doi: 10.1158/1078-0432.CCR-05-0891Chen PC, Yu HJ, Chang YH, Pan CC. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol. 2013;66(2):113–119. doi: 10.1136/jclinpath-2012-200944Chen P.C., Yu H.J., Chang Y.H., Pan C.C. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression // J Clin Pathol. 2013. Vol. 66, N 2. P. 113–119. doi: 10.1136/jclinpath-2012-200944Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer. 2002;101(1):1–6. doi: 10.1002/ijc.10544Hafner C., Knuechel R., Stoehr R., Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies // Int J Cancer. 2002. Vol. 101, N 1. P. 1–6. doi: 10.1002/ijc.10544Wu BK, Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 2014;9(5):1827–1840. doi: 10.1016/j.celrep.2014.10.063Wu B.K., Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation // Cell Rep. 2014. Vol. 9, N 5. P. 1827–1840. doi: 10.1016/j.celrep.2014.10.063Heyn H, Sayols S, Moutinho C, et al. Linkage of DNA methylation quantitative trait loci to human cancer risk. Cell Rep. 2014;7(2):331–338. doi: 10.1016/j.celrep.2014.03.016Heyn H., Sayols S., Moutinho C., et al. Linkage of DNA methylation quantitative trait loci to human cancer risk // Cell Rep. 2014. Vol. 7, N 2. P. 331–338. doi: 10.1016/j.celrep.2014.03.016Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003;63(23):8108-8112.Bakkar A.A., Wallerand H., Radvanyi F., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder // Cancer Res. 2003. Vol. 63, N 23. P. 8108–8112.Tabin CJ, Bradley SM, Bargmann CI, et al. Mechanism of activation of a human oncogene. Nature. 1982;300(5888):143–149. doi: 10.1038/300143a0Tabin C.J., Bradley S.M., Bargmann C.I., et al. Mechanism of activation of a human oncogene // Nature. 1982. Vol. 300, N 5888. P. 143–149. doi: 10.1038/300143a0Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001;20(16):1973–1980. doi: 10.1038/sj.onc.1204315Zhang Z.T., Pak J., Huang H.Y., et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation // Oncogene. 2001. Vol. 20, N 16. P. 1973–1980. doi: 10.1038/sj.onc.1204315Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322. doi: 10.1038/nature12965Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma // Nature. 2014. Vol. 507, N 7492. P. 315–322. doi: 10.1038/nature12965Cheng J, Huang H, Pak J, et al. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer research. 2003;63(1):179–185.Cheng J., Huang H., Pak J., et al. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder // Cancer research. 2003. Vol. 63, N 1. P. 179–185.Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62(3):809–818.Hartmann A., Schlake G., Zaak D., et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder // Cancer Res. 2002. Vol. 62, N 3. P. 809–818.Kim J, Akbani R, Creighton CJ, et al. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res. 2015;21(20):4514–4524. doi: 10.1158/1078-0432.CCR-14-1215Kim J., Akbani R., Creighton C.J., et al. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise // Clin Cancer Res. 2015. Vol. 21, N 20. P. 4514–4524. doi: 10.1158/1078-0432.CCR-14-1215Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17–37. doi: 10.1016/j.cell.2013.03.002Garraway L.A., Lander E.S. Lessons from the cancer genome // Cell. 2013. Vol. 153, N 1. P. 17–37. doi: 10.1016/j.cell.2013.03.002Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Natl Canc Inst. 2012;24(4):151–159. doi: 10.1016/j.jnci.2012.08.002Zaghloul M.S. Bladder cancer and schistosomiasis // J Egypt Natl Canc Inst. 2012. Vol. 24, N 4. P. 151–159. doi: 10.1016/j.jnci.2012.08.002Lopez-Beltran A, Escudero AL, Vicioso L, et al. Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br J Cancer. 1996;73(1):124–127. doi: 10.1038/bjc.1996.23Lopez-Beltran A., Escudero A.L., Vicioso L., et al. Human papillomavirus DNA as a factor determining the survival of bladder cancer patients // Br J Cancer. 1996. Vol. 73, N 1. P. 124–127. doi: 10.1038/bjc.1996.23De Gaetani C, Ferrari G, Righi E, et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation. J Clin Pathol. 1999;52(2):103–106. doi: 10.1136/jcp.52.2.103De Gaetani C., Ferrari G., Righi E., et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation // J Clin Pathol. 1999. Vol. 52, N 2. P. 103–106. doi: 10.1136/jcp.52.2.103Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol. 1995;27(2):104–109. doi: 10.1159/000475138Aso Y., Akaza H., Kotake T., et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group // Eur Urol. 1995. Vol. 27, N 2. P. 104–109. doi: 10.1159/000475138Yan Y, Chen YN, Zhao Q, et al. Helicobacter pylori infection with intestinal metaplasia: An independent risk factor for colorectal adenomas. World J Gastroenterol. 2017;23(8):1443–1449. doi: 10.3748/wjg.v23.i8.1443Yan Y., Chen Y.N., Zhao Q., et al. Helicobacter pylori infection with intestinal metaplasia: An independent risk factor for colorectal adenomas // World J Gastroenterol. 2017. Vol. 23, N 8. P. 1443–1449. doi: 10.3748/wjg.v23.i8.1443Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–215. doi: 10.1016/j.chom.2013.07.007Kostic A.D., Chun E., Robertson L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment // Cell Host Microbe. 2013. Vol. 14, N 2. P. 207–215. doi: 10.1016/j.chom.2013.07.007O’Donnell MA. Does the probiotic L. casei help prevent recurrence after transurethral resection for superficial bladder cancer? Nat Clin Pract Urol. 2008;5(10):526–527. doi: 10.1038/ncpuro1199O’Donnell M.A. Does the probiotic L. casei help prevent recurrence after transurethral resection for superficial bladder cancer? // Nat Clin Pract Urol. 2008. Vol. 5, N 10. P. 526–527. doi: 10.1038/ncpuro1199Wu P, Zhang G, Zhao J, et al. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. Front Cell Infect Microbiol. 2018;8:167. doi: 10.3389/fcimb.2018.00167.Wu P., Zhang G., Zhao J., et al. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China // Front Cell Infect Microbiol. 2018. Vol. 8, N. P. 167. doi: 10.3389/fcimb.2018.00167Bucevic Popovic V, Situm M, Chow CT, et al. The urinary microbiome associated with bladder cancer. Sci Rep. 2018;8(1):12157. doi: 10.1038/s41598-018-29054-wBucevic Popovic V., Situm M., Chow C.T., et al. The urinary microbiome associated with bladder cancer // Sci Rep. 2018. Vol. 8, N 1. P. 12157. doi: 10.1038/s41598-018-29054-wHernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664–3671. doi: 10.1200/JCO.2005.05.1771Hernandez S., Lopez-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas // J Clin Oncol. 2006. Vol. 24, N 22. P. 3664–3671. doi: 10.1200/JCO.2005.05.1771